ClinicalTrials.gg
RecruitingNCT07855627Updated Oct 2, 2026

Prediction Of Lymphedema In Patients With Inflammatory BreastCancer Using Preoperative Bioimpedance Measurements

An observational study in Lymphedema, Inflammatory Breast Cancer (IBC) and Preoperative, sponsored by M.D. Anderson Cancer Center. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by M.D. Anderson Cancer Center · Observational

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Oct 2, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
150
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 168 studies in Lymphedema with a site in United States — 37 open to participants now, 45 under way, 1 of them phase 3. Lymphedema · United States.

Planned enrollment
22nd of 44
150 · median 148
Started
2026
with 6 others
Observational
44 of 168
14 open now
Primary completion
2027-12
later than 28 of 44 live
Registered
168th of 168
by date
Lead sponsor
7 of 168
M.D. Anderson Cancer Center

Among the 168 studies in Lymphedema with a site in United States, this one is the 22nd largest by planned enrollment of the 44 observational ones that give a count, is one of 7 that started in 2026, is one of 44 observational ones, reaches primary completion later than 28 of the 44 other live ones, and was the 168th registered.

Lymphedema

529 studies on the registry are indexed under Lymphedema; 129 are open to participants now.

Browse Lymphedema studies →

Open to participants now

37 of the 168 studies in Lymphedema with a site in United States are open now. Recruiting first, the newest first:

31 more — sign in →

All 37 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 84 Lymphedema studies recruiting now, 46 (55%) set no upper age limit and 21 (25%) stop at 75 or younger; 5 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 168 studies in Lymphedema with a site in United States, or all of them as a file.
02

Study summary

To find out whether the BIA test can help identify participants with IBC who are at risk for developing lymphedema.

Read the detailed description

Primary Objectives The primary objective is to reliably describe risk factors for development of BCRL in IBC using BIA.

03

Conditions studied

  • Lymphedema
  • Inflammatory Breast Cancer (IBC)
  • Preoperative
  • Bioimpedance Measurement
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

UT MD Anderson Cancer Center

Eligibility criteria

Eligibility Criteria All women≥18 years old with newly diagnosed inflammatory breast cancer without prior breast/axillary surgery who are eligible for standard of care (NST, MRM, and radiation therapy).

Exclusion Criteria Prior breast/axillary surgery. Participants with pacemakers or other implanted electronic medical devices. Participants with implanted metallic material. All vulnerable populations, including children, pregnant women, and cognitively impaired adult

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
150 participants (estimated)
Patient registry
No

Interventions

  • DrugNeoadjuvant therapy

    all patients will start/continue neoadjuvant systemic therapy

06

What researchers measure

Primary outcomes

  1. Lymphedema Life Impact Scale (LLIS) questionnaire

    Time frame: Through study completion; an average of 1 year.

07

Study locations

1 of 1 sites recruiting
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Dec 2027, 15 months after the start.

Of 56 non-industry observational studies under Lymphedema, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 108. This study's planned 15 months is below that.

Counting every sponsor, half of 59 studies reached it within 45 months; a quarter within 12 and three quarters within 108.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2026
First posted
Oct 2, 2026
StartActual
Sep 16, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2029
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07855627
Responsible party
Sponsor
First posted
Oct 2, 2026
Start date
Sep 16, 2026
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Oct 2, 2026

Study contacts

Anthony Lucci, MD
Contact
ALucci@mdanderson.org
713-563-1871
Anthony Lucci, MD
principal investigator · UT MD Anderson Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion